Search 

Healthcare Venture Capital Fund headquartered in Shangahi

国家纳米科学院与广东

chbd

A Chengdu Based Chinese Pharmaceutical Company with focus on both Brand- Name/Generic Product Development, Manufacturing and Supply in Both Domestic and International Markets. Annual revenue is more than 175 million USD. We also have medical devices business unit starting from 2020.

Founded in 2005, Baiyu is dedicated to R&D, manufacturing and marketing high-quality pharmaceutical products and APIs to all patients. As an innovation-based pharmaceutical company, we are specializing in chemical/botanical/biological medicinal products, especially ginkgo pharmaceutical products. And in 2020, aiming to protect everyone’s healthcare, Baiyu has built own subsidiary to produce high quality of Personal Protective Equipment to worldwide market.

With more than 1,300 employees and 8 wholly owned subsidiaries, Baiyu has a rich pipeline of products launched for neuropsychiatric, cardio-cerebrovascular, anti-tumor, respiratory, digestive, anti-infective areas along with many products under development. And Ginkgolide injection is the first innovative botanical injectable approved since the implementation of Drug Registration Regulation (2007), of which the active ingredient contents reach up to 99%.

Currently, several production lines have obtained GMP certificates, and new factories meeting EU&US GMP requirements with fully automatic and intelligent operations have been built to accelerate Baiyu’s globalization process.

Brilliant was founded in Chengdu city in 2007, specializes in the manufacturing and sale of generic medicines, innovative biologicals, small molecules and inhaled preparations. The sales revenue in 2019 was nearly US $550 million. We have 5 R&D centers and 5 GMP factories.

Chengdu Jian River Pharmaceutical Co., Ltd. was established in 2019 with a registered capital of 20 million yuan. The establishment of jianRiver serves Sichuan Development (Holdings) Co., Ltd. and the people's Government of Pengzhou City to set up a "Pengzhou Fund". For Tianfu traditional Chinese Medicine City in the global recruitment and incubation of pharmaceutical projects, through docking funds to provide professional management and services to provide support for the growth of the project. As the main body of the construction and operation of the innovation incubator in Pengzhou Tianfu traditional Chinese Medicine City, relying on rich project channel resources and professional service team, it is committed to helping excellent modern Chinese medicine research and development enterprises, new drug research and development enterprises, cutting-edge biotechnology companies, medical device companies and large health industry related enterprises to accurately land in Pengzhou, through the whole industry chain services such as professional incubation acceleration, achievement transformation and financial investment. Promote the rapid development of innovative start-up enterprises. Adhering to the concept that "high-quality projects are the foundation of industrial development, and first-class talents are the core force of project growth", Jian River will gather high-quality projects to jointly build a high-quality medicine and large-scale health project incubation base in Pengzhou. Help more outstanding top entrepreneurial talents to realize their entrepreneurial ideals.

Chengdu Kanghong Pharmaceutical Co., Ltd. is a pharmaceutical company integrating R & D and production. Kanghong has involved in the fields of traditional Chinese medicine, chemical medicine, biological medicine and medical devices. One of the products- conbercept, first in class has been developing in more than 30 countries in the world.

CTTQ is a leading big pharma with integrated R&D, manufacturing, marketing, and sales in China. We are the markter leader in drugs treating liver disease and cancer in China. CTTQ is a subsidiary of Sino Biopharmaceutical Ltd., which has been listed on Hong Kong Stock Exchange since 2003. Currently CTTQ has more than 10,000 employees, with total revenue of RMB 23 billion (USD$3.2 B) in 2019.

We are looking for cooperation opportunities with pharma/biotech companies via licensing and R & D collaboration in the following areas: Innovative small molecule and biologics products in therapeutic areas of oncology, liver, infectious, respiratory, cardiovascular, and metabolic diseases, etc.

Founded in May 1989, China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) is the national indUnited Statestrial association in China devoted to promote international trade and investment in the healthcare sector.

CCCMHPIE has a diverse membership including the major R&D facilities, manufactures, trading companies and investment institutions in China, ranging from pharmaceuticals, medical devices and equipment, biopharmaceuticals, traditional Chinese medicines, nutraceuticals, functional cosmetics to foods for special medical purposes. It is a professional trade and investment promotion organization in the Chinese healthcare sector while serving as the bridge between authorities and enterprises as well as Chinese and foreign partners.